Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody

Teclistamab is a BCMAxCD3 bispecific antibody, the first approved for the treatment of relapsed or refractory multiple myeloma. Given its impressive efficacy in heavily pretreated patients and better accessibility compared to BCMA-directed CAR T cells, teclistamab is sure to become a staple of relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Darren, Richter, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368105/
https://www.ncbi.nlm.nih.gov/pubmed/37497430
http://dx.doi.org/10.2147/CMAR.S372237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368105/
https://www.ncbi.nlm.nih.gov/pubmed/37497430
http://dx.doi.org/10.2147/CMAR.S372237

Ejemplares similares